Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm


Release Date: July 31, 2018
Expiration Date: July 31, 2019
Media: Internet-based

Activity Overview

Physicians’ Education Resource®, LLC (PER®) is pleased to present the CME-certified online activity titled, Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm. This innovative activity is an archived version of the live-streamed Medical Crossfire® held on June 25, 2018, at the American Diabetes Association’s 78th Scientific Sessions.

With new clinical trial data surrounding available and emerging treatments for diabetes continually being published in the literature, studies evaluating these drugs are growing increasingly complex. Thus, there is a need among clinicians who treat patients with type 2 diabetes (T2D) to collaborate with leading experts on the disease to differentiate the various therapies in terms of their mechanisms of action, potential for adverse events, and, perhaps most importantly, to understand how a drug might be synergistically combined to individualize and improve the care and clinical outcomes of patients with T2D.

To meet those needs, this symposium assessed the benefits and limitations of currently available antihyperglycemic therapies as well as the most common reasons patients with T2D fail to achieve target glycated hemoglobin (A1C) and cardiometabolic risk factor goals. Our faculty of nationally recognized experts investigated and differentiated the mechanisms of action of various plasma glucose-lowering therapies, including SGLT2 inhibitors; discussed the therapeutic advantages of targeting their novel pathways; and analyzed the clinical trial data surrounding SGLT2 inhibitor therapy in patients with T2D at various stages of the disease. Finally, a panel discussion and audience question-and-answer session helped clinicians understand how to improve outcomes in patients with diabetes by selecting appropriate and effective therapies that tighten glycemic control, reduce overall cardiometabolic risk, and achieve beneficial outcomes in patients with T2D.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc, administered by Janssen Scientific Affairs, LLC

Target Audience

This educational activity is directed toward physicians.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Articulate reasons that persons with type 2 diabetes (T2D) fail to achieve target A1C goals and reduce cardiometabolic risk factors
  • List the potential clinical benefits for achieving glycemic control with newer therapies, especially SGLT2 inhibitors, in persons with T2D and cardiometabolic risk factors at various stages of the disease
  • Discuss results of recent large-scale cardiovascular outcomes trials in persons with T2D
  • Develop individualized approaches for effectively improving outcomes in persons with T2D and cardiometabolic risk factors

Faculty, Staff, and Planners’ Disclosures


Program Chair

Vivian A. Fonseca, MD, FRCP 
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis–Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Disclosure: Grant/Research Support: Asahi, Bayer, Boehringer Ingelheim; Consultant/Speakers Bureau: AstraZeneca, Eli Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda; Other/Honoraria for CME Lectures: AstraZeneca, Eli Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda
 

Program Moderator

Stephen A. Brunton, MD, FAFP
Executive Director
Primary Care Metabolic Group (PCMG)
Palm Springs, California
 
 
 
Disclosure: Consultant/Speakers Bureau: Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Sanofi

Faculty

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Section of Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
Yale-New Haven Hospital
New Haven, Connecticut
 
Disclosure: Consultant/Speakers Bureau: Janssen, VTV Pharmaceuticals; Other/Honoraria for CME Lectures: Clinical trial/steering/executive/publications committees: AstraZeneca, Boehringer Ingelheim, Eisai (TIMI), Novo Nordisk, Sanofi/Lexicon; Data Monitoring Committee: Intarcia
 

James L. Januzzi, MD
Director, Dennis and Marilyn Barry
Fellowship in Cardiology Research
Massachusetts General Hospital
Hutter Family Professor of Medicine
Harvard Medical School
Cardiometabolic Trials
Baim Institute for Clinical Research
Boston, Massachusetts
 
Disclosure: Grant/Research Support: Boehringer Ingelheim, Janssen; Consultant/Speakers Bureau: Janssen

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.
 
Faculty, Staff, and Reviewer Disclosure Statement: All faculty, staff, and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships will be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of Physicians’ Education Resource, LLC, and Purdue University College of Pharmacy have no relationships to disclose.
 

Accreditation Statement

Physician Accreditation Statement – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Physicians’ Education Resource, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Credit Designation Purdue University College of Pharmacy designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

For information about the accreditation of this program, please contact  Dawn Sinclair, sinclaid@purdue.edu, Accreditation Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding accreditation designation or Heather Holley, hholley@purdue.edu, Reconciliation and Outcomes Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding CE credit received and/or certificates.
 
 
 
 
 

Related CME Activites
NY CERC Clinical Connections
Expires on
December 29, 2018
CME
1.0






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By